A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults

Purpose

The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.

Condition

  • Healthy

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy males aged 18 to 45 years and healthy females aged 18 to 55 years - Body Mass Index (BMI) of 16-32 kg/m2, and a total body weight greater than 50 kg (110 lb); for Japanese participants only, a total body weight greater than 45 kg - for Japanese participants only, enrolling as Japanese must have 4 biological grandparents who were born in Japan.

Exclusion Criteria

  • Evidence or history of clinically significant medical or psychiatric conditions - Prior or current use of any prohibited medications - History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening - Pregnant or breastfeeding females, males with partners currently pregnant, or males or females pursuing artificial reproductive technologies - Use of tobacco/nicotine containing products

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Other
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
PF-07314470; Cohorts 1 to 7, optional Cohort 8 and optional Japanese Cohort 14 		Participants will receive a single dose of PF-07314470 at 1 of 7 dose levels
  • Biological: PF-07314470
    subcutaneous injection
Placebo Comparator
Placebo for PF-07314470; Cohorts 1 to 7, optional Cohort 8 and optional Japanese Cohort 14 		Participants will receive a single dose of placebo for PF-07314470
  • Biological: Placebo for PF-07314470
    subcutaneous injection
Experimental
PF-07314470; Cohorts 9 to 13 		Participants will receive PF-07314470 weekly at 1 of 4 dose levels for 4 doses, or every 2 weeks at 1 dose level for 3 doses.
  • Biological: PF-07314470
    subcutaneous injection
Placebo Comparator
Placebo for PF-07314470; Cohorts 9 to 13 		Participants will receive placebo for PF-07314470 weekly for 4 doses, or every 2 weeks for 3 doses.
  • Biological: Placebo for PF-07314470
    subcutaneous injection

Recruiting Locations

More Details

NCT ID
NCT06821750
Status
Terminated
Sponsor
Pfizer

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center